AstraZeneca PLC (AZN)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $286.07B
Last updated: Nov 17, 2026 at 11:05 AM ET
AstraZeneca PLC (AZN) P/E Ratio & Valuation History
AstraZeneca (AZN) trades at 22.5x trailing earnings and 4.6x sales. Its P/E of 22.5x is below its 5-year median of 37.6x. Its forward P/E is 16.3x. The median P/E across 9 similar companies is 19.9x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 38.0% higher over the next year. Its free cash flow yield is 3.2%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 22.5x |
| Forward P/E | 16.3x |
| Price to sales | 4.6x |
| Price to book | 5.6x |
| EV/EBITDA | 14.6x |
| Price to FCF | 30.9x |
| EV/FCF | 33.4x |
| PEG | 1.3 |
| FCF yield | 3.2% |
Historical Medians
Against its 10-year medians, its P/E is 43.3% below 39.7x, its P/S is 9.5% above 4.2x and its P/B is 5.1% below 5.9x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 22.5x | 37.6x | 39.7x |
| P/S | 4.6x | 4.3x | 4.2x |
| P/B | 5.6x | 5.5x | 5.9x |
Valuation History
Over the 10 year ends shown, its P/E ranged from 25.2x in 2016 to 64.0x in 2019.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $183.86 | 30.9x | 4.9x | 5.9x |
| 2024 | $131.04 | 31.9x | 3.8x | 5.0x |
| 2023 | $134.70 | 37.0x | 4.6x | 5.4x |
| 2022 | $135.60 | 40.6x | 3.2x | 5.7x |
| 2021 | $116.50 | 44.0x | 3.4x | 2.3x |
| 2020 | $99.98 | 48.1x | 4.9x | 8.4x |
| 2019 | $99.72 | 64.0x | 3.6x | 10.0x |
| 2018 | $75.96 | 42.3x | 4.4x | 7.7x |
| 2017 | $69.40 | 32.3x | 3.9x | 5.9x |
| 2016 | $54.64 | 25.2x | 3.0x | 4.7x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About AZN
What is AZN's forward P/E ratio?
AstraZeneca has a forward P/E ratio of 16.3x.
Is AZN stock overvalued?
GNG's valuation label for AZN is Undervalued. Its P/E of 22.5x compares with a median of 19.9x across 9 similar companies.
What is AZN's price to sales ratio?
AstraZeneca has a price to sales ratio of 4.6x.
What is AstraZeneca's average P/E ratio over 5 years?
AstraZeneca's median P/E over the last 5 years is 37.6x, from 60 month-end values through Oct 2026.
What is AZN's PEG ratio?
AstraZeneca has a PEG ratio of 1.3.
AZN pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts